CClinicalTrials.gg
Status unknownNCT01708668EIEBFLAUpdated Jan 15, 2015

The Effects of Intermittent Epidural Bolus on Fever During Labor Analgesia

An interventional study of Epidural analgesia and Combined spinal-epidural analgesia in Labor Pain, Pain and Neurologic Manifestations, sponsored by ShanWu Feng, M.D.. Status unknown at 1 site in China. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-01-15.

Sponsored by ShanWu Feng, M.D. · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2015), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
12,000
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

Epidural analgesia is associated with maternal intra-partum fever during labor. Intermittent epidural injections appear to reduce the incidence of maternal intra-partum fever compared to continuous epidural infusion during labor analgesia. However, the optimal combination of bolus volume and administrating interval has not yet been compared. The purpose of this prospective, randomized, double-blind trial was to determine how intermittent epidural bolus reduced the incidence of maternal intra-partum fever compared with continuous epidural infusion during labor.

02

Conditions studied

  • Labor Pain
  • Pain
  • Neurologic Manifestations
  • Signs and Symptoms
  • Pathological Conditions, Signs and Symptoms

Keywords

  • Fever
  • Patient controlled epidural analgesia
  • Labor analgesia
  • Epidural analgesia
  • Combined spinal-epidural analgesia
03

In context

Neurologic Manifestations

198 studies on the registry are indexed under Neurologic Manifestations; 67 are open to participants now.

This study's planned enrollment of 12,000 is above the median of 40 across 107 interventional studies indexed under Neurologic Manifestations.

Browse Neurologic Manifestations studies →

Lead sponsor

This is the only study on the registry with ShanWu Feng, M.D. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Nulliparous women
  • Required labor analgesia
  • Chinese
  • Spontaneous labor

Exclusion criteria

Exclusion Criteria:

  • Contraindications for epidural analgesia
  • Allergic to opioids and/or local anesthetics
  • Failed to performing epidural catheterization
  • Organic dysfunction
  • Those who were not willing to or could not finish the whole study at any time
  • Using or used in the past 14 days of the monoamine oxidase inhibitors
  • Alcohol addictive or narcotic dependent patients
  • Subjects with a nonvertex presentation or scheduled induction of labor
  • Twin gestation and breech presentation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
12,000 participants (estimated)

Study arms

  • Active comparator
    1

    Epidural analgesia (EA) with continuous epidural infusion(CEI)

    Procedure: Epidural analgesia · Procedure: Continuous epidural infusion

  • Active comparator
    2

    Combined spinal-epidural analgesia (CSEA) with continuous epidural infusion(CEI)

    Procedure: Combined spinal-epidural analgesia · Procedure: Continuous epidural infusion

  • Active comparator
    3

    Epidural analgesia (EA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)

    Procedure: Epidural analgesia · Procedure: Intermittent epidural bolus

  • Active comparator
    4

    Epidural analgesia (EA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)

    Procedure: Epidural analgesia · Procedure: Intermittent epidural bolus

  • Active comparator
    5

    Epidural analgesia (EA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)

    Procedure: Epidural analgesia · Procedure: Intermittent epidural bolus

  • Active comparator
    6

    Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)

    Procedure: Combined spinal-epidural analgesia · Procedure: Intermittent epidural bolus

  • Active comparator
    7

    Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)

    Procedure: Combined spinal-epidural analgesia · Procedure: Intermittent epidural bolus

  • Active comparator
    8

    Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)

    Procedure: Combined spinal-epidural analgesia · Procedure: Intermittent epidural bolus

Interventions

  • ProcedureEpidural analgesia
  • ProcedureCombined spinal-epidural analgesia
  • ProcedureContinuous epidural infusion
  • ProcedureIntermittent epidural bolus
06

What researchers measure

Primary outcomes

  1. Maternal oral and tympanic temperature

    Time frame: At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)

Secondary outcomes

  1. Maternal serum Interleukin-1β

    Time frame: At time of placental delivery and 3, 6 and 12 hours later

  2. Cord serum Interleukin-1β

    Time frame: At time of placental delivery

  3. Maternal serum Interleukin-6

    Time frame: At time of placental delivery and 3, 6 and 12 hours later

  4. Cord serum Interleukin-6

    Time frame: At time of placental delivery

  5. Maternal serum Interleukin-10

    Time frame: At time of placental delivery and 3, 6 and 12 hours later

  6. Cord serum Interleukin-10

    Time frame: At time of placental delivery

  7. Maternal serum tumor necrosis factor-α

    Time frame: At time of placental delivery and 3, 6 and 12 hours later

  8. Cord serum tumor necrosis factor-α

    Time frame: At time of placental delivery

  9. Regression and correlation analyses between maternal and cord serum cytokines

    Time frame: At twelve hours postpartum

  10. Placental routine pathologic examination

    Time frame: At time of placental delivery

  11. Maternal and cord blood gase analysis

    Time frame: At time of placental delivery

  12. Maternal modified Bromage scale and visual analogue scale

    Time frame: At time of initiation of analgesia and hourly thereafter until 2 hours postpartum (approximately 10 hours)

  13. Rescue boluses, n of rescue boluses, and the consumption of the ropivacaine/sufentanil mixture

    Time frame: At two hours postpartum

  14. Rates of cesarean delivery and instrument-assisted delivery

    Time frame: At time of placental delivery

  15. Indications of cesarean delivery

    Time frame: Initiation of analgesia to placental delivery (approximately 8 hours)

  16. Duration of analgesia

    Time frame: Initiation of analgesia to 2 h postpartum (approximately 10 hours)

  17. Durations of labor stages

    Time frame: From the beginning of regular contraction of uterus to the end of the labor (approximately 12 hours)

  18. Maternal satisfaction with analgesia

    Time frame: At two hours postpartum

  19. Use of oxytocin after analgesia

    Time frame: At twenty-four hours postpartum

  20. Low back pain at 3 months after vaginal delivery

    Time frame: At the third month after vaginal delivery

  21. Breastfeeding success at 6 weeks after vaginal delivery

    Time frame: At the sixth week after successful delivery

  22. Neonatal Apgar scale

    Time frame: At the first and fifth minutes after baby was born

  23. Incidence of maternal side effects

    Time frame: Initiation of analgesia to 2 hour postpartum (approximately 10 hours)

  24. Neonatal Neurologic and Adaptive Capacity Score

    Time frame: At 30 min, 2 h, and 24 h after baby was born

  25. Maximal oxytocin dose

    Time frame: At twenty-four hours postpartum

  26. Neonatal sepsis evaluation

    Time frame: At 30 min after baby was born

  27. Neonatal antibiotic treatment

    Time frame: One week after baby was born

  28. Maternal heart rate, respiratory rate, and blood pressure

    Time frame: At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)

  29. Highest thoracic sensory level to alcohol

    Time frame: At three hours after initiation of analgesia

  30. Uterine contraction

    Time frame: At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)

  31. Neonatal rectal temperature

    Time frame: At delivery, 30 min after delivery, and 1 h after delivery

  32. Fetal heart rate

    Time frame: From initiation of analgesia to delivery (approximately 8 hours)

  33. Maternal group B streptococcus (GBS) colonization

    Time frame: At time of initiation of analgesia

  34. Number of vaginal examinations, duration from rupture of the membranes to delivery, mode of membranes ruptured

    Time frame: From initiation of analgesia to delivery (approximately 8 hours)

  35. Neonatal weight

    Time frame: At delivery

  36. Uterine artery, umbilical artery and vein, fetus middle cerebral artery by ultrasound

    Time frame: At time of initiation of analgesia and hourly thereafter until delivery (approximately 8 hours)

  37. Maternal serum epinephrine, norepinephrine, insulin, glucagon, corticotropin releasing hormone, adrenocorticotropic hormone, cortisol, blood glucose, oxytocin, prostaglandin E2 and prostaglandin F2 alpha

    Time frame: At time of initiation of analgesia and hourly thereafter until 4 hours postpartum (approximately 12 hours)

  38. Maternal postpartum depression

    Time frame: At time of delivery and daily thereafter until 1 year postpartum (approximately 1 year)

07

Study locations

1 of 1 sites recruiting
  • Nanjing Maternal and Child Health Care Hospital Affiliated to Nanjing Medical University
    Nanjing, Jiangsu 210004, China
    • Shanwu Feng, M.D. · Contact · shanwufeng@163.com · +86 25 52226112
    • Shanwu Feng, M.D. · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01708668
Lead sponsor
ShanWu Feng, M.D.
Responsible party
ShanWu Feng, M.D. (Department of Anesthesiology, Nanjing Maternal and Child Health Care Hospital, Nanjing, Jiangsu, China, 210004, Nanjing Medical University) — Sponsor-investigator
First posted
Oct 17, 2012
Start date
Oct 2012
Primary completion
Jul 2015 (estimated)
Completion
Jun 2017 (estimated)
Last update
Jan 15, 2015

Study contacts

Shanwu Feng, M.D.
Contact
shanwufeng@163.com
+86 25 52226112
Shanwu Feng, M.D.
study director · Nanjing Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion